Topical Administration of a Marine Oil Rich in Pro-Resolving Lipid Mediators Accelerates Wound Healing in Diabetic db/db Mice through Angiogenesis and Macrophage Polarization.

Fecha de publicación: 31/08/2022 Fecha Ahead of Print: 31/08/2022

Autores de IIS La Fe

Imelda Ontoria Oviedo

Autor
Delia Castellano Izquierdo

Autor
Cristina Pelacho Lopez

Autor
Pilar Sepúlveda Sanchis

Autor

Participantes ajenos a IIS La Fe

Amaro-Prellezo, Elena
Venegas-Venegas, Elena
Gonzalez-Santos, Fernando
Ruiz-Sauri, Amparo
Prosper, Felipe
Perez del Caz, Maria Dolores

Grupos

Regeneración y Trasplante Cardíaco

Leader

Pilar Sepúlveda Sanchis

Abstract

Impaired wound healing in patients with type 2 diabetes (DM2) is characterized by chronic inflammation, which delays wound closure. Specialized pro-resolving lipid mediators (SPMs) are bioactive molecules produced from essential polyunsaturated fatty acids (PUFAs), principally omega-3 docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). SPMs are potent regulators of inflammation and have been used to suppress chronic inflammation in peripheral artery disease, non-alcoholic fatty liver disease, and central nervous system syndromes. LIPINOVA(R) is a commercially available safe-grade nutritional supplement made from a fractionated marine lipid concentrate derived from anchovy and sardine oil that is rich in SPMs and EPA, as well as DHA precursors. Here, we assessed the effect of LIPINOVA(R) in wound dressing applications. LIPINOVA(R) showed biocompatibility with keratinocytes and fibroblasts, reduced the abundance of pro-inflammatory macrophages (M phi 1), and promoted in vitro wound closure. Daily application of the marine oil to open wounds made by punch biopsy in db/db mice promoted wound closure by accelerating the resolution of inflammation, inducing neoangiogenesis and M phi 1/M phi 2 macrophage polarization. In conclusion, LIPINOVA(R) displays pro-resolutive properties and could be exploited as a therapeutic agent for the treatment of diabetic ulcers.

Datos de la publicación

ISSN/ISSNe:: 1661-6596, 1661-6596
Tipo:: Article
Páginas:: -
DOI:: 10.3390/ijms23179918
Factor de Impacto:: 1,176 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Ontoria-Oviedo, Imelda:: Instituto de Investigación. Regenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain
Amaro-Prellezo, Elena:: Instituto de Investigación. Regenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain
Castellano, Delia:: Instituto de Investigación. Regenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain
Venegas-Venegas, Elena:: Solutex GC, S.L., Parque Empresarial Utebo, 50180 Utebo, Spain
Gonzalez-Santos, Fernando:: Solutex GC, S.L., Parque Empresarial Utebo, 50180 Utebo, Spain
Ruiz-Sauri, Amparo:: Departamento de Patología, Facultad de Medicina, Instituto de Investigación Sanitaria INCLIVA, Universitat de Valencia, 46026 Valencia, Spain
Pelacho, Beatriz:: Regenerative Medicine Department, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, 31008 Pamplona, Spain
Prosper, Felipe:: Regenerative Medicine Department, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, 31008 Pamplona, Spain

Departamento de Hematología y Terapia Celular, Clínica Universidad de Navarra, 31008 Pamplona, Spain
Perez del Caz, Maria Dolores:: Instituto de Investigación. Regenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain
Sepulveda, Pilar:: Instituto de Investigación. Regenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain

CIBERCV, Carlos III Institute of Health, 28029 Madrid, Spain